Australia markets open in 8 hours 59 minutes

The9 Limited (NCTY)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.17-0.44 (-7.84%)
As of 10:52AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.61
Bid0.00 x 0
Ask0.00 x 0
Day's range4.90 - 6.00
52-week range3.33 - 14.70
Avg. volume55,559
Market cap28.871M
Beta (5Y monthly)1.92
PE ratio (TTM)N/A
EPS (TTM)-36.45
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date29 Jan 2009
1y target estN/A
  • PR Newswire

    The9 Limited Achieved 66% Increase in Net Revenues and Turned Net Loss into Net Income for the Year Ended December 31, 2023

    The9 Limited (NASDAQ: NCTY) ("The9"), an established Internet company, today announced it filed its annual report on Form 20-F for the year ended December 31, 2023 with the United States Securities and Exchange Commission ("SEC"). The annual report, which contains The9's audited financial statements, can be assessed on the SEC's website at as well as on the Investor Relations section of The9's website at

  • PR Newswire

    A New Generation of Antidepressant Drug Precision Treatment Based on Revolutionary AI Technology is Born

    The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that its investee WM Therapeutics Co., Ltd. (未名脑脑) ("WM Therapeutics") has achieved revolutionary breakthroughs in the proprietarily developed research and development of antidepressant drug precision treatment. WM Therapeutics' GenAI multi-dimensional omics drug clinical research technology has made significant progress in new clinical trial, bringing new hope to depression patients.

  • PR Newswire

    /C O R R E C T I O N -- The9 Limited/

    The9 Limited (Nasdaq: NCTY) ("The9"), an established Internet company, today announced that it signed a definitive share purchase agreement (the "Agreement") with WM Therapeutic Co., Ltd. ("WM Therapeutic"), a company operating Generative AI (GenAI) large language model (LLM) multi-dimensional and multi-omics digital precision medicine platform for brain disease, to purchase an additional 21.7% shares of WM Therapeutic by cash and issuance of The9's restricted shares. The9 had invested 8.3% shar